Response to: 'Treatment adherence of patients with sytemic rheumatic diseases in COVID-19 pandemic' by Fragoulis et al

Affiliations

¹ Division of Rheumatology and Clinical Immunology, Department of Medicine IV, Ludwig Maximilians University Munich, Munich, Germany hendrik.schulze-koops@med.uni-muenchen.de.
² Praxiszentrum St. Bonifatius, Munich, Germany.
³ Klinik für Rheumatologie und Klinische Immunologie, KEM Kliniken Essen-Mitte, Essen, Germany.

Comment

Hendrik Schulze-Koops et al. Ann Rheum Dis. 2021 Apr.

. 2021 Apr;80(4):e61.

doi: 10.1136/annrheumdis-2020-217987. Epub 2020 May 31.

¹ Division of Rheumatology and Clinical Immunology, Department of Medicine IV, Ludwig Maximilians University Munich, Munich, Germany hendrik.schulze-koops@med.uni-muenchen.de.
² Praxiszentrum St. Bonifatius, Munich, Germany.
³ Klinik für Rheumatologie und Klinische Immunologie, KEM Kliniken Essen-Mitte, Essen, Germany.

No abstract available

Keywords: arthritis, rheumatoid; autoimmune diseases; inflammation.

Conflict of interest statement

Competing interests: None declared.

Preliminary recommendations of the German Society of Rheumatology (DGRh eV) for the management of patients with inflammatory rheumatic diseases during the SARS-CoV-2/COVID-19 pandemic.
Schulze-Koops H, Specker C, Iking-Konert C, Holle J, Moosig F, Krueger K. Schulze-Koops H, et al. Ann Rheum Dis. 2020 Jun;79(6):840-842. doi: 10.1136/annrheumdis-2020-217628. Epub 2020 Apr 28. Ann Rheum Dis. 2020. PMID: 32345619 No abstract available.
Treatment adherence of patients with systemic rheumatic diseases in COVID-19 pandemic.
Fragoulis GE, Evangelatos G, Arida A, Bournia VK, Fragiadaki K, Karamanakos A, Kravvariti E, Laskari K, Panopoulos S, Pappa M, Tektonidou MG, Sfikakis PP. Fragoulis GE, et al. Ann Rheum Dis. 2021 Apr;80(4):e60. doi: 10.1136/annrheumdis-2020-217935. Epub 2020 May 31. Ann Rheum Dis. 2021. PMID: 32475830 No abstract available.